Could Legalizing Marijuana Curb Mexican Drug Violence?
Could Legalizing Marijuana Curb Mexican Drug Violence? – Complete video at: fora.tv Beau Kilmer and Richard Lee debate the potential effects marijuana legalization in California could have on Mexican drug cartels. Kilmer cites that California only accounts for a small percentage of the cartels’ revenue, while Lee counters that legalization in California could lead to legalization nationwide. —– Will California become the first state to legalize the production and sale of marijuana? November ballot measure Proposition 19 would allow local governments to choose whether and how to regulate and tax marijuana. Some are concerned about legalization’s effect on consumption and public health, while others tout the potential boon to city and state coffers. Besides the jaw-dropping estimated retail price decrease from 0 to per ounce, nothing is really certain about the potential impact of Prop 19. Get informed before the vote — don’t miss advocates of both sides arguing the pros and cons of pushing pot through the legal pipeline. – Commonwealth Club of California Beau Kilmer is codirector of the RAND Drug Policy Research Center. His primary fields of interest are illicit markets, community corrections, drug treatment, and the future of drug testing. Kilmer’s recent work focused on measuring the size of the global drug market for the European Commission and developing indicators to measure the impact of drug enforcement in Europe. His current work focuses on identifying the community-level effects of drug treatment and …
FAQ: What you need to know about health insurance 'open enrollment'
Filed under: San Francisco Drug Treatment Centers
"It is a little bit like tax season and it's a little bit like voting, too where it takes some work to make a good choice, says David Sayen, regional administrator of the Centers for Medicare and Medicaid Services (CMS) Region IX in San Francisco …
Read more on 89.3 KPCC
BioCryst Pharmaceuticals and Presidio Pharmaceuticals to Merge
Filed under: San Francisco Drug Treatment Centers
In addition to BCX5191 and BCX4161, BioCryst's drug development portfolio includes peramivir, a viral neuraminidase inhibitor for the treatment of influenza in Phase 3 development, and ulodesine, a Phase 3 ready purine nucleoside phosphorylase (PNP …
Read more on DailyFinance